What marketing authorization means for prescribing decisions

The article describes the regulatory approval process and its relevance to clinical prescribing. The European Medicines Agency (EMA) or national regulators assess submitted evidence, usually including clinical trials, to determine whether a medicine’s benefits outweigh its risks for the studied population and approved indication. Approval does not require a medicine to outperform existing treatments. The decision and authorized information are reflected in the product summary (SmPC) and patient leaflet; pricing is handled separately.

Use outside the approved terms—including for a different indication, age group, dose or administration method—is considered off label. In these cases, regulators have not assessed the benefit–risk balance for that use. The authors state that physicians carry increased responsibility to establish an evidence basis, inform the patient and document their reasoning. Off-label use may be supported by evidence, but in some cases studies may be absent. The article also notes that use without Swedish marketing authorization requires a licensing process.

For newly approved medicines, the authors recommend consulting the EMA’s European Public Assessment Report (EPAR), which summarizes the evidence and regulatory benefit–risk assessment. They caution that pivotal-trial populations may exclude children, pregnant people and patients with comorbidities, leaving evidence gaps after approval. The piece is an educational article, not a new clinical study; it also emphasizes reporting suspected adverse reactions, particularly those not listed in the product information and those involving recently approved medicines.